Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 30.40%
March 31, 2026 -55.33%
December 31, 2025 -143.1%
September 30, 2025 -243.0%
June 30, 2025 43.74%
March 31, 2025 -5.80%
December 31, 2024 56.17%
September 30, 2024 13.43%
June 30, 2024 8.40%
March 31, 2024 40.41%
December 31, 2023 62.03%
September 30, 2023 -4.26%
June 30, 2023 -48.92%
March 31, 2023 -11.03%
December 31, 2022 -7.15%
September 30, 2022 45.76%
June 30, 2022 12.22%
March 31, 2022 -3.43%
December 31, 2021 63.46%
September 30, 2021 -64.24%
June 30, 2021 1.96%
March 31, 2021 -16.87%
December 31, 2020 53.44%
September 30, 2020 54.65%
June 30, 2020 51.77%
Date Value
March 31, 2020 -339.6%
December 31, 2019 -105.6%
September 30, 2019 -14.87%
June 30, 2019 -80.93%
March 31, 2019 15.58%
December 31, 2018
September 30, 2018 82.38%
June 30, 2018 -265.0%
March 31, 2018 -662.6%
December 31, 2017 -729.4%
September 30, 2017 -706.1%
June 30, 2017 -175.9%
March 31, 2017 -165.6%
December 31, 2016 -145.8%
September 30, 2016 -198.4%
June 30, 2016 -503.1%
March 31, 2016 -822.9%
December 31, 2015 -479.7%
September 30, 2015 -424.2%
June 30, 2015 -447.9%
March 31, 2015 -600.1%
December 31, 2014 -2.27K%
September 30, 2014 -21.84K%
June 30, 2014 -453.2%
March 31, 2014 -615.6%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 8.65%
Corcept Therapeutics, Inc. 16.45%
Veru, Inc. --
Johnson & Johnson 0.83%
Eli Lilly & Co. 30.88%